Genus Capital Management Inc. bought a new position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,100 shares of the company's stock, valued at approximately $5,563,000.
A number of other hedge funds and other institutional investors have also modified their holdings of HCA. Norges Bank bought a new stake in shares of HCA Healthcare during the 4th quarter worth about $840,286,000. GAMMA Investing LLC raised its position in shares of HCA Healthcare by 40,527.3% in the first quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company's stock valued at $5,887,850,000 after purchasing an additional 1,699,713 shares during the period. Royal London Asset Management Ltd. boosted its holdings in shares of HCA Healthcare by 62.0% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,500,786 shares of the company's stock worth $450,461,000 after buying an additional 574,239 shares during the period. Barclays PLC raised its holdings in HCA Healthcare by 85.7% in the 4th quarter. Barclays PLC now owns 1,061,891 shares of the company's stock worth $318,727,000 after acquiring an additional 489,916 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in HCA Healthcare by 12,016.0% during the fourth quarter. Two Sigma Investments LP now owns 467,437 shares of the company's stock valued at $140,301,000 after acquiring an additional 463,579 shares during the period. Institutional investors own 62.73% of the company's stock.
HCA Healthcare Stock Performance
NYSE:HCA traded up $4.36 on Monday, hitting $380.43. The company's stock had a trading volume of 935,591 shares, compared to its average volume of 1,587,036. The company has a current ratio of 1.19, a quick ratio of 1.06 and a debt-to-equity ratio of 69.07. The firm has a market capitalization of $91.52 billion, a P/E ratio of 16.92, a price-to-earnings-growth ratio of 1.30 and a beta of 1.47. HCA Healthcare, Inc. has a one year low of $289.98 and a one year high of $417.14. The stock has a fifty day moving average of $375.13 and a two-hundred day moving average of $342.25.
HCA Healthcare (NYSE:HCA - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported $6.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.75 by $0.70. HCA Healthcare had a net margin of 8.07% and a return on equity of 1,063.91%. The company had revenue of $18.32 billion during the quarter, compared to analysts' expectations of $18.26 billion. During the same quarter last year, the company posted $5.36 EPS. HCA Healthcare's quarterly revenue was up 5.7% compared to the same quarter last year. Research analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.
HCA Healthcare Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 16th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend was Monday, June 16th. HCA Healthcare's dividend payout ratio is 12.81%.
Insider Transactions at HCA Healthcare
In other news, COO Jon M. Foster sold 15,698 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the sale, the chief operating officer directly owned 12,646 shares of the company's stock, valued at approximately $4,670,420.72. This represents a 55.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on HCA shares. Royal Bank Of Canada reissued an "outperform" rating and issued a $404.00 price objective (up from $376.00) on shares of HCA Healthcare in a research report on Monday, June 23rd. Stephens upgraded shares of HCA Healthcare to a "strong-buy" rating in a research note on Monday, June 2nd. Robert W. Baird reiterated a "neutral" rating and set a $336.00 target price (down from $396.00) on shares of HCA Healthcare in a research report on Tuesday, April 15th. Wells Fargo & Company upgraded shares of HCA Healthcare from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $320.00 to $385.00 in a research note on Thursday, May 29th. Finally, Baird R W downgraded HCA Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 15th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, HCA Healthcare has an average rating of "Moderate Buy" and an average target price of $395.71.
Read Our Latest Report on HCA Healthcare
About HCA Healthcare
(
Free Report)
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Further Reading
Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
